Virtus LifeSci Biotech Clinical Trials ETF
19 hedge funds and large institutions have $18.2M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.28% less ownership
Funds ownership: 38.91% → 36.63% (-2.3%)
Holders
19
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
1 | +$2.09M | |
2 | +$562K | |
3 | +$544K | |
4 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
+$410K |
5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$290K |
Top Sellers
1 | -$2.43M | |
2 | -$38K | |
3 | -$7K | |
4 |
FCM
Firestone Capital Management
Coral Gables,
Florida
|
-$1K |